Off-target activity inhibitors for guided endonucleases

Richard Alexander Notebaart (Inventor), Tim Andreas Künne (Inventor), Stan Johan Jozef Brouns (Inventor), John Van Der Oost (Inventor)

Research output: Patent


Incidence of off-target DNA cleavage when using CRISPR Cas systems for gene modification are lessened or avoided by using oligonucleotides of rational design and which are antisense to target sequence of the guide RNA or other targeting nucleic acid sequence. Whether in vitro or in vivo, a target nucleic acid comprising a targeted sequence is exposed to the CRISPR enzyme and relevant guiding RNA (or ribonucleoprotein complex) with the antisense oligonucleotide. The antisense oligonucleotide is exposed to the target nucleic acid substantially simultaneously, separately or sequentially together with the CRISPR enzyme or ribonucleoprotein complex.

Original languageEnglish
Patent numberWO2020065062
Priority date28/09/18
Publication statusPublished - 2 Apr 2020


Dive into the research topics of 'Off-target activity inhibitors for guided endonucleases'. Together they form a unique fingerprint.

Cite this